Dr.DITSHA DATTA

Dr.Perwez Khan

Abstract

Aim:

To evaluate the safety and efficacy of Suprachoroidally administered Anti VEGF(bevacizumab) in patients of wet ARMD .

Materials and Methods:

The study included patients diagnosed of Wet ARMD . Only one eye per patient was included. Suprachoroidal injection of anti VEGF(bevacizumab) was administered by an indigenously designed needle( the patent for which has been filed). The needle can be inserted in a range of 500-900 um depth;depending upon the patient’s scleral thickness. 0.1 ml of the drug is injected into the Suprachoroidal space and followed up for 3months.

Results:

Most patients had a prompt improvement in visual acuity, which was maintained up till 3months.

Conclusion:

Suprachoroidal anti VEGF is an efficacious treatment option for wet age related macular edema as it is basically a choroidal pathology. By depositing the drug in suprachoroidal space just next to the pathological tissue i.e choroid a better result is obtained.

Full Text